These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 22929980)

  • 1. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study.
    Visco C; Tzankov A; Xu-Monette ZY; Miranda RN; Tai YC; Li Y; Liu WM; d'Amore ES; Li Y; Montes-Moreno S; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Wang HY; Dunphy CH; His ED; Zhao XF; Choi WW; Zhao X; van Krieken JH; Huang Q; Ai W; O'Neill S; Ponzoni M; Ferreri AJ; Kahl BS; Winter JN; Go RS; Dirnhofer S; Piris MA; Møller MB; Wu L; Medeiros LJ; Young KH
    Haematologica; 2013 Feb; 98(2):255-63. PubMed ID: 22929980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
    Johnson NA; Slack GW; Savage KJ; Connors JM; Ben-Neriah S; Rogic S; Scott DW; Tan KL; Steidl C; Sehn LH; Chan WC; Iqbal J; Meyer PN; Lenz G; Wright G; Rimsza LM; Valentino C; Brunhoeber P; Grogan TM; Braziel RM; Cook JR; Tubbs RR; Weisenburger DD; Campo E; Rosenwald A; Ott G; Delabie J; Holcroft C; Jaffe ES; Staudt LM; Gascoyne RD
    J Clin Oncol; 2012 Oct; 30(28):3452-9. PubMed ID: 22851565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified.
    Yan LX; Liu YH; Luo DL; Zhang F; Cheng Y; Luo XL; Xu J; Cheng J; Zhuang HG
    PLoS One; 2014; 9(8):e104068. PubMed ID: 25090026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.
    Hu S; Xu-Monette ZY; Tzankov A; Green T; Wu L; Balasubramanyam A; Liu WM; Visco C; Li Y; Miranda RN; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Zhao X; van Krieken JH; Huang Q; Huh J; Ai W; Ponzoni M; Ferreri AJ; Zhou F; Slack GW; Gascoyne RD; Tu M; Variakojis D; Chen W; Go RS; Piris MA; Møller MB; Medeiros LJ; Young KH
    Blood; 2013 May; 121(20):4021-31; quiz 4250. PubMed ID: 23449635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
    Green TM; Young KH; Visco C; Xu-Monette ZY; Orazi A; Go RS; Nielsen O; Gadeberg OV; Mourits-Andersen T; Frederiksen M; Pedersen LM; Møller MB
    J Clin Oncol; 2012 Oct; 30(28):3460-7. PubMed ID: 22665537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.
    Ye Q; Xu-Monette ZY; Tzankov A; Deng L; Wang X; Manyam GC; Visco C; Montes-Moreno S; Zhang L; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Møller MB; Piris MA; Winter JN; Medeiros LJ; Hu S; Young KH
    Oncotarget; 2016 Jan; 7(3):2401-16. PubMed ID: 26573234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
    J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab.
    Iqbal J; Meyer PN; Smith LM; Johnson NA; Vose JM; Greiner TC; Connors JM; Staudt LM; Rimsza L; Jaffe E; Rosenwald A; Ott G; Delabie J; Campo E; Braziel RM; Cook JR; Tubbs RR; Gascoyne RD; Armitage JO; Weisenburger DD; Chan WC
    Clin Cancer Res; 2011 Dec; 17(24):7785-95. PubMed ID: 21933893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma.
    Horn H; Ziepert M; Becher C; Barth TF; Bernd HW; Feller AC; Klapper W; Hummel M; Stein H; Hansmann ML; Schmelter C; Möller P; Cogliatti S; Pfreundschuh M; Schmitz N; Trümper L; Siebert R; Loeffler M; Rosenwald A; Ott G;
    Blood; 2013 Mar; 121(12):2253-63. PubMed ID: 23335369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab.
    Akyurek N; Uner A; Benekli M; Barista I
    Cancer; 2012 Sep; 118(17):4173-83. PubMed ID: 22213394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
    Ennishi D; Jiang A; Boyle M; Collinge B; Grande BM; Ben-Neriah S; Rushton C; Tang J; Thomas N; Slack GW; Farinha P; Takata K; Miyata-Takata T; Craig J; Mottok A; Meissner B; Saberi S; Bashashati A; Villa D; Savage KJ; Sehn LH; Kridel R; Mungall AJ; Marra MA; Shah SP; Steidl C; Connors JM; Gascoyne RD; Morin RD; Scott DW
    J Clin Oncol; 2019 Jan; 37(3):190-201. PubMed ID: 30523716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inferior survival in high-grade B-cell lymphoma with
    McPhail ED; Maurer MJ; Macon WR; Feldman AL; Kurtin PJ; Ketterling RP; Vaidya R; Cerhan JR; Ansell SM; Porrata LF; Nowakowski GS; Witzig TE; Habermann TM
    Haematologica; 2018 Nov; 103(11):1899-1907. PubMed ID: 29903764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
    Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S
    J BUON; 2015; 20(3):820-8. PubMed ID: 26214636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
    Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
    J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study.
    Tzankov A; Leu N; Muenst S; Juskevicius D; Klingbiel D; Mamot C; Dirnhofer S
    J Hematol Oncol; 2015 Jun; 8():70. PubMed ID: 26071053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MYC rearrangement and MYC/BCL2 double expression but not cell-of-origin predict prognosis in R-CHOP treated diffuse large B-cell lymphoma.
    Xu J; Liu JL; Medeiros LJ; Huang W; Khoury JD; McDonnell TJ; Tang G; Schlette E; Yin CC; Bueso-Ramos CE; Lin P; Li S
    Eur J Haematol; 2020 Apr; 104(4):336-343. PubMed ID: 31944390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab.
    Perry AM; Alvarado-Bernal Y; Laurini JA; Smith LM; Slack GW; Tan KL; Sehn LH; Fu K; Aoun P; Greiner TC; Chan WC; Bierman PJ; Bociek RG; Armitage JO; Vose JM; Gascoyne RD; Weisenburger DD
    Br J Haematol; 2014 May; 165(3):382-91. PubMed ID: 24506200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Significance of
    Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
    Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
    [No Abstract]   [Full Text] [Related]  

  • 19. Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers.
    Pedersen MØ; Gang AO; Brown P; Pedersen M; Knudsen H; Nielsen SL; Poulsen T; Wirenfeldt Klausen T; Høgdall E; Nørgaard P
    PLoS One; 2017; 12(10):e0186983. PubMed ID: 29088292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. R-CHOP regimen can significantly decrease the risk of disease relapse and progression in patients with non-germinal center B-cell subtype diffuse large B-cell lymphoma.
    He XH; Li B; Yang S; Lu N; Zhang X; Zou SM; Li YX; Song YW; Zheng S; Dong M; Zhou SY; Yang JL; Liu P; Zhang CG; Qin Y; Feng FY; Shi YK
    Chin J Cancer; 2012 Jun; 31(6):306-14. PubMed ID: 22640627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.